SCHEMBL19699267

SCHEMBL19699267

O=[N+]([O-])c1cc(COc2ncnc3c2ncn3[C@H]2C[C@@H](O)[C@@H](COP(=O)(O)O)O2)cc(COP(=O)(O)O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.51
ENPP1 P22413 3/20 0.51
P2RY1 P47900 2/20 0.51
SLC29A1 Q99808 1/20 0.49
DNPH1 O43598 5/20 0.49
TYMS P04818 1/20 0.46
NT5E P21589 1/20 0.43
PRKAB2 O43741 1/20 0.43
TRPM2 O94759 1/20 0.43
LDHA P00338 1/20 0.43
ADRB2 P07550 1/20 0.43
FBP1 P09467 1/20 0.43
SRC P12931 1/20 0.43
ADORA1 P30542 1/20 0.43
P2RY2 P41231 1/20 0.43
PRKAG1 P54619 1/20 0.43
PRKAA2 P54646 1/20 0.43
PDE4D Q08499 1/20 0.43
KCNH2 Q12809 1/20 0.43
PRKAA1 Q13131 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19699283 0.93 POLB (0.58) POLBENPP1P2RY1DNPH1NT5E
SCHEMBL19699254 0.90 POLB (0.56) POLBENPP1P2RY1DNPH1NT5E
SCHEMBL19699244 0.89 POLB (0.54) POLBENPP1P2RY1DNPH1NT5E
SCHEMBL19699252 0.88 POLB (0.55) POLBENPP1P2RY1SLC29A1DNPH1
SCHEMBL19699243 0.84 POLB (0.53) POLBENPP1P2RY1DNPH1NT5E
SCHEMBL19699225 0.81 POLB (0.61) POLBENPP1P2RY1DNPH1NT5E
SCHEMBL19699234 0.78 DNPH1 (0.64) POLBENPP1P2RY1DNPH1
SCHEMBL19699255 0.77 DNPH1 (0.57) POLBENPP1P2RY1SLC29A1DNPH1
SCHEMBL1533828 0.77 POLB (0.65) POLBENPP1P2RY1DNPH1NT5E
SCHEMBL1533826 0.77 POLB (0.65) POLBENPP1P2RY1DNPH1NT5E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-07-09 US disclosed
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-12-14 US disclosed
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof RNGTT, UPF1, NSUN3 POLB 59/4885ENPP1 1187/4885P2RY1 1963/4885
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF RNGTT, UPF1, NSUN3 POLB 60/4885ENPP1 1203/4885P2RY1 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.